Research programme: protein therapeutics - VirvioAlternative Names: HB36.6
Latest Information Update: 06 Jan 2017
At a glance
- Originator Virvio
- Developer The Scripps Research Institute; University of Washington; Utah State University; Virvio
- Class Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 04 Feb 2016 Preclinical trials in Influenza virus infections in USA (Intranasal)